Embla Medical hf (FRA:5IQ) reports robust sales growth and profitability, despite facing hurdles in the patient care segment and European markets.

Embla Medical hf (OSSUY) reports a 15% revenue increase and 21% net profit growth, despite challenges in EBITDA margin and gross profit.

Embla Medical hf (CPSE:EMBLA) is in focus after reporting fourth quarter and full year 2025 results, with higher sales and net income figures that help frame how the stock’s recent performance might be interpreted. See our latest analysis for Embla Medical hf. The latest earnings release comes after a tougher period for the stock, with a 30 day share price return of 8.54% and a 1 year total shareholder return decline of 13.04%, hinting that recent operational progress has not yet translated...

Embla Medical hf (OSSUY) reports robust organic sales growth and strategic advancements despite challenges in the Americas and patient care sectors.

If you are wondering what to make of Embla Medical hf right now, you are definitely not alone. The stock has caught the attention of investors who are keen on understanding its next move, especially after a year of pretty flat action. Over the last 12 months, Embla Medical hf shares are right where they started, showing a 0.0% return. However, longer-term holders are still underwater, with a painful drop of 32.7% over five years. Recent weeks have offered a mild glimmer of optimism, as shares...